Codex DNA, Inc. (NASDAQ:DNAY – Get a rating) benefited from a significant drop in short-term interest in April. As of April 30, there was short interest totaling 1,000,000 shares, a decrease of 27.0% from the April 15 total of 1,370,000 shares. Based on an average daily volume of 328,400 shares, the day-to-cover ratio is currently 3.0 days. About 11.5% of the stock’s shares are sold short.
Institutional investors have recently changed their positions in the stock. Citigroup Inc. increased its stake in Codex DNA by 221.0% during the fourth quarter. Citigroup Inc. now owns 2,838 shares of the company valued at $31,000 after purchasing an additional 1,954 shares in the last quarter. Wells Fargo & Company MN increased its stake in Codex DNA shares by 1,245.5% in Q4. Wells Fargo & Company MN now owns 3,606 shares of the company valued at $39,000 after purchasing 3,338 additional shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Codex DNA in Q3, valued at approximately $47,000. American International Group Inc. purchased a new stake in Codex DNA stock in Q3, valued at approximately $47,000. Finally, Deutsche Bank AG bought a new equity stake in Codex DNA in Q3 valued at around $50,000. 87.58% of the shares are held by institutional investors.
Several research companies have recently published reports on DNAY. Cowen began covering Codex DNA in a research report on Wednesday, March 2. They set a “buy” rating for the company. KeyCorp reduced its price target on Codex DNA from $30.00 to $8.00 and set an “overweight” rating for the company in a Monday, March 28 research report. To finish, Zacks Investment Research upgraded Codex DNA from a “sell” rating to a “hold” rating in a Monday, May 2 research report.
Shares of Codex DNA Stockpile opened at $3.81 on Friday. The stock has a 50-day moving average of $5.74 and a 200-day moving average of $7.35. Codex DNA has a 12 month minimum of $3.43 and a 12 month maximum of $25.70. The company has a market capitalization of $112.01 million and a PE ratio of -1.67. The company has a current ratio of 9.57, a quick ratio of 9.33 and a debt ratio of 0.16.
Codex DNA (NASDAQ:DNAY – Get a rating) last announced its quarterly results on Wednesday, May 11. The company reported ($0.45) EPS for the quarter, beating analyst consensus estimates of ($0.50) by $0.05. Codex DNA had a negative return on equity of 43.84% and a negative net margin of 311.52%. As a group, equity research analysts expect Codex DNA to post earnings per share of -2.04 for the current fiscal year.
Codex DNA Company Profile (Get a rating)
Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, related products and related services primarily to pharmaceutical and academic laboratories worldwide. Its solutions include the BioXp system that allows researchers to go from digital DNA sequence to endpoint-ready synthetic DNA; the BioXp Portal, an online portal that offers intuitive guided workflow and design tools for creating new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; cloud-based scripts; Benchtop reagents that contain all the reagents needed to perform a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which allows a customer to order and receive BioXp System endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and enzymatic DNA synthesis by assembly of short oligoligatures.
Get news and reviews for Codex DNA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Codex DNA and related companies with MarketBeat.com’s free daily email newsletter.